| P2093 | author name string | Clifford Lingwood | |
| P2860 | cites work | Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer | Q21090050 |
| | The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1 | Q24563989 |
| | Unique multipotent cells in adult human mesenchymal cell populations | Q24631550 |
| | Shiga Toxin Increases Formation of Clathrin-Coated Pits through Syk Kinase | Q27325579 |
| | The RNA-N-glycosidase activity of Shiga-like toxin I: kinetic parameters of the native and activated toxin | Q73952496 |
| | Cerebrovascular damage in young rabbits after intravenous administration of Shiga toxin 2 | Q74625763 |
| | Proteolytic cleavage of the A subunit is essential for maximal cytotoxicity of Escherichia coli O157:H7 Shiga-like toxin-1 | Q77905375 |
| | Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells | Q79298186 |
| | Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation | Q81753789 |
| | Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome | Q90390380 |
| | Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome | Q90602690 |
| | Rescue from Stx2-Producing E. coli-Associated Encephalopathy by Intravenous Injection of Muse Cells in NOD-SCID Mice | Q90677995 |
| | To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps | Q90950007 |
| | Structural Insights into Escherichia coli Shiga Toxin (Stx) Glycosphingolipid Receptors of Porcine Renal Epithelial Cells and Inhibition of Stx-Mediated Cellular Injury Using Neoglycolipid-Spiked Glycovesicles | Q91378647 |
| | Shiga toxin binding alters lipid packing and the domain structure of Gb3-containing membranes: a solid-state NMR study | Q91577380 |
| | Neurotrophic Factor Secretion and Neural Differentiation Potential of Multilineage-differentiating Stress-enduring (Muse) Cells Derived from Mouse Adipose Tissue | Q91872943 |
| | Rab7b participation on the TLR4 (Toll-like receptor) endocytic pathway in Shiga toxin-associated Hemolytic Uremic Syndrome (HUS) | Q92458425 |
| | Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study | Q92614519 |
| | Synthetic construction of sugar-amino acid hybrid polymers involving globotriaose or lactose and evaluation of their biological activities against Shiga toxins produced by Escherichia coli O157:H7 | Q93014903 |
| | Quantitative Analysis of SSEA3+ Cells from Human Umbilical Cord after Magnetic Sorting | Q93172606 |
| | Muse Cell: A New Paradigm for Cell Therapy and Regenerative Homeostasis in Ischemic Stroke | Q93360518 |
| | Clinical Trials of Muse Cells | Q93360554 |
| | Future of Muse Cells | Q93360561 |
| | Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli | Q93363230 |
| | Sulfatide-Hsp70 interaction promotes Hsp70 clustering and stabilizes binding to unfolded protein | Q41196128 |
| | Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues | Q41474149 |
| | Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. | Q41575546 |
| | Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells | Q41614148 |
| | Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. | Q42065084 |
| | A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins | Q42078905 |
| | The ATPase domain of hsp70 possesses a unique binding specificity for 3'-sulfogalactolipids | Q42635324 |
| | A soluble sulfogalactosyl ceramide mimic promotes Delta F508 CFTR escape from endoplasmic reticulum associated degradation | Q42688247 |
| | Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis | Q42913459 |
| | An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. | Q42947533 |
| | Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis | Q43152766 |
| | Effect of a soluble pseudo-receptor on verotoxin 2-induced toxicity | Q43473818 |
| | Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance | Q43738152 |
| | Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease | Q44285559 |
| | 3'Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro | Q44309804 |
| | Brefeldin A and filipin distinguish two globotriaosyl ceramide/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity | Q44854735 |
| | Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice | Q44901937 |
| | Rab12 localizes to Shiga toxin-induced plasma membrane invaginations and controls toxin transport. | Q45749762 |
| | Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool | Q46440038 |
| | Differential binding of Shiga toxin 2 to human and murine neutrophils | Q46927601 |
| | A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab | Q47144392 |
| | Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. | Q47622602 |
| | Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt's lymphoma cells | Q50025664 |
| | Clustering of PK-trisaccharides on amphiphilic cyclodextrin reveals unprecedented affinity for the Shiga-like toxin Stx2. | Q50169925 |
| | Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome. | Q51361622 |
| | Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. | Q51783073 |
| | Conformational analysis of blood group A-active glycosphingolipids using HSEA-calculations. The possible significance of the core oligosaccharide chain for the presentation and recognition of the A-determinant. | Q52516061 |
| | Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. | Q53819914 |
| | Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. | Q54238876 |
| | Monovalent Gb3-/Gb2-derivatives conjugated with a phosphatidyl residue: a novel class of Shiga toxin-neutralizing agent. | Q54434683 |
| | Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins. | Q54590916 |
| | Verotoxin-binding in human renal sections. | Q54644479 |
| | Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content | Q54683456 |
| | Verotoxin receptor glycolipid in human renal tissue. | Q54736253 |
| | Membrane cytosolic translocation of verotoxin A1 subunit in target cells. | Q54737751 |
| | Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. | Q54764104 |
| | The retromer component sorting nexin-1 is required for efficient retrograde transport of Shiga toxin from early endosome to the trans Golgi network. | Q55044041 |
| | Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome | Q56373628 |
| | Biochemical, pathological and oncological relevance of Gb3Cer receptor | Q57117659 |
| | Orientation of the saccharide chains of glycolipids at the membrane surface: conformational analysis of the glucose-ceramide and the glucose-glyceride linkages using molecular mechanics (MM3) | Q57137853 |
| | Eculizumab in STEC-HUS: need for a proper randomized controlled trial | Q57173405 |
| | Lipid Modulation of Glycosphingolipid (GSL) Receptors: Soluble GSL Mimics Provide New Probes of GSL Receptor Function | Q57363615 |
| | Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor–mediated apoptosis by regulating Lyn kinase activity in human B cells | Q57363943 |
| | Cholesterol modulates glycolipid conformation and receptor activity | Q57889172 |
| | The effects of globotriaosylceramide tail saturation level on bilayer phases | Q60194868 |
| | The structure of the Shiga toxin 2a A-subunit dictates the interactions of the toxin with blood components | Q64237937 |
| | Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function | Q67913265 |
| | Globotetraosylceramide is recognized by the pig edema disease toxin | Q69517260 |
| | LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL | Q71455795 |
| | Capping and receptor-mediated endocytosis of cell-bound verotoxin (Shiga-like toxin). 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization | Q72809655 |
| | A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans | Q73505003 |
| | Renal and neurological involvement in typical Shiga toxin-associated HUS. | Q33403361 |
| | Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome | Q33415691 |
| | Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolytic-uremic syndrome | Q33424584 |
| | Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome | Q33425759 |
| | Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab | Q33426242 |
| | Risk of haemolytic uraemic syndrome caused by shiga-toxin-producing Escherichia coli infection in adult women in Japan | Q33426758 |
| | Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome. | Q33432541 |
| | The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli | Q33457864 |
| | Lipid reorganization induced by Shiga toxin clustering on planar membranes | Q33482809 |
| | A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome | Q33489393 |
| | Partial complement deficiencies in idiopathic thrombocytopenia of childhood | Q33491081 |
| | Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. | Q33496269 |
| | How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40). | Q33530071 |
| | Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases | Q33599604 |
| | Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). | Q33694188 |
| | Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. | Q33889513 |
| | Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes | Q33944092 |
| | Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose | Q34006601 |
| | Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration | Q34009274 |
| | Analysis of acrylamide, a carcinogen formed in heated foodstuffs | Q34143312 |
| | RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes | Q34163395 |
| | Vero response to a cytotoxin of Escherichia coli | Q34177128 |
| | The use of Shiga-like toxin 1 in cancer therapy | Q34288923 |
| | Shiga toxin regulates its entry in a Syk-dependent manner | Q34407232 |
| | Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2 | Q34589587 |
| | Shiga toxin induces tubular membrane invaginations for its uptake into cells | Q34719609 |
| | Shiga toxin subtypes display dramatic differences in potency | Q34739913 |
| | Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. | Q34897367 |
| | Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism | Q35065197 |
| | Retrograde transport of toxins across the endoplasmic reticulum membrane | Q35594208 |
| | Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial Ghosts | Q35947400 |
| | Structure-dependent pseudoreceptor intracellular traffic of adamantyl globotriaosyl ceramide mimics | Q35956792 |
| | Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases | Q36217769 |
| | Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. | Q36265701 |
| | Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands | Q27621547 |
| | Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli | Q27644365 |
| | Molecular Basis of Differential B-Pentamer Stability of Shiga Toxins 1 and 2 | Q27666433 |
| | The Crystal Structure of Shiga Toxin Type 2 with Bound Disaccharide Guides the Design of a Heterobifunctional Toxin Inhibitor | Q27680604 |
| | Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3 | Q27748877 |
| | Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis | Q28239591 |
| | Rapid Apoptosis Induced by Shiga Toxin in HeLa Cells | Q30310781 |
| | CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation | Q30442733 |
| | Mechanism of Shiga Toxin Clustering on Membranes | Q30841698 |
| | Peptides binding to a Gb3 mimic selected from a phage library | Q33205254 |
| | The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer | Q33229926 |
| | A globotriaosylceramide (Gb3Cer) mimic peptide isolated from phage display library expressed strong neutralization to Shiga toxins | Q33244168 |
| | A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin | Q33261570 |
| | Apparent cooperativity in multivalent verotoxin-globotriaosyl ceramide binding: kinetic and saturation binding studies with [(125)I]verotoxin | Q33332657 |
| | Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome | Q33332898 |
| | Escherichia coli Shiga toxin. | Q33334138 |
| | Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli | Q33335879 |
| | Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome | Q33337835 |
| | Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. | Q33339549 |
| | Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome | Q33346480 |
| | Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands | Q33346643 |
| | Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial | Q33349877 |
| | Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. | Q33358728 |
| | Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome | Q33368588 |
| | Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia | Q33372623 |
| | Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes | Q33373408 |
| | Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157. | Q33377746 |
| | Interactions between Shiga toxins and human polymorphonuclear leukocytes | Q33380350 |
| | Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology | Q33383255 |
| | Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro | Q33384145 |
| | Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli | Q33388849 |
| | Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration | Q33389052 |
| | New immuno-PCR assay for detection of low concentrations of shiga toxin 2 and its variants | Q36539801 |
| | Soluble adamantyl glycosphingolipid analogs as probes of glycosphingolipid function | Q36637790 |
| | In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins | Q36950791 |
| | An acidic sequence within the cytoplasmic domain of furin functions as a determinant of trans-Golgi network localization and internalization from the cell surface | Q37623766 |
| | ERAD substrates: which way out? | Q37660718 |
| | Shiga toxin and its use in targeted cancer therapy and imaging | Q37831422 |
| | How ricin and Shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum | Q37901423 |
| | A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. | Q38294429 |
| | An entropically efficient supramolecular inhibition strategy for Shiga toxins | Q38295070 |
| | Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins | Q38300698 |
| | Interaction of the Shiga-like toxin type 1 B-subunit with its carbohydrate receptor | Q38301508 |
| | Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. | Q38315562 |
| | Adamantyl globotriaosyl ceramide: a monovalent soluble mimic which inhibits verotoxin binding to its glycolipid receptor | Q38326124 |
| | Investigation of Shiga-like Toxin Binding to Chemically Synthesized Oligosaccharide Sequences | Q38332110 |
| | Induction of cytokines by toxins that have an identical RNA N-glycosidase activity: Shiga toxin, ricin, and modeccin | Q38343493 |
| | Glycosphingolipids: structure, biological source, and properties | Q38766443 |
| | Shiga toxin stimulates clathrin-independent endocytosis of the VAMP2, VAMP3 and VAMP8 SNARE proteins. | Q38864468 |
| | Regulation of cytokine and chemokine expression by the ribotoxic stress response elicited by Shiga toxin type 1 in human macrophage-like THP-1 cells | Q39376598 |
| | Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding | Q39560067 |
| | Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies | Q39986916 |
| | ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. | Q40003950 |
| | Colocalization of receptors for Shiga toxins with lipid rafts in primary human renal glomerular endothelial cells and influence of D-PDMP on synthesis and distribution of glycosphingolipid receptors | Q40202145 |
| | Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. | Q40293264 |
| | Lipo-oligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. | Q40825138 |
| | Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains | Q40915784 |
| | The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit | Q40949783 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P304 | page(s) | 123 | |
| P577 | publication date | 2020-03-31 | |
| P1433 | published in | Frontiers in Cellular and Infection Microbiology | Q27724376 |
| P1476 | title | Verotoxin Receptor-Based Pathology and Therapies | |
| P478 | volume | 10 | |